Fluidigm Announces Third Quarter 2018 Financial Results
01 nov. 2018 16h05 HE
|
Fluidigm Corporation
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018...
Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD
04 oct. 2018 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a non-exclusive distribution agreement with DNA Software,...
Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
01 oct. 2018 16h15 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report...
Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1
27 sept. 2018 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced two new total RNA sequencing...
Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD
07 sept. 2018 07h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded Immuno-Oncology Gene Expression Workflow to...
Fluidigm Announces Second Quarter 2018 Financial Results
02 août 2018 16h05 HE
|
Fluidigm Corporation
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE...
Fluidigm Introduces a Lower-Cost Workflow for Full-Length Single-Cell mRNA Sequencing on C1
31 juil. 2018 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new full-length single-cell mRNA...
Fluidigm Announces First Multimodal Single-Cell Application for the C1
10 juil. 2018 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new bimodal single‑cell application...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
05 juil. 2018 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass...
Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service
07 juin 2018 07h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based genomic...